Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | GAA | P10253 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | SNCA | P37840 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8372271 | 0.90 | KMT2A (0.77) | TP53GAAKMT2AMEN1L3MBTL1 | |
| SCHEMBL8713312 | 0.90 | MEN1 (0.81) | TP53GAAKMT2AMEN1L3MBTL1 | |
| SCHEMBL18416918 | 0.87 | HTT (0.68) | TP53GAAKMT2AMEN1L3MBTL1 | |
| SCHEMBL2033537 | 0.87 | MEN1 (0.74) | TP53GAAKMT2AMEN1MAPT | |
| SCHEMBL4251085 | 0.86 | MAPT (0.70) | TP53GAAKMT2AMEN1L3MBTL1 | |
| SCHEMBL28894148 | 0.86 | TP53 (1.00) | TP53GAAKMT2AMEN1L3MBTL1 | |
| SCHEMBL18459114 | 0.86 | KMT2A (0.59) | TP53GAAKMT2AMEN1L3MBTL1 | |
| SCHEMBL14288427 | 0.85 | MEN1 (0.68) | TP53GAAKMT2AMEN1MAPT | |
| SCHEMBL29961069 | 0.85 | MAPT (0.69) | KMT2AMEN1MAPTALDH1A1MAPK1 | |
| SCHEMBL27451088 | 0.84 | SNCA (0.57) | TP53GAAKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030859-B2 | Polymerizable compound, polymerizable composition and optical film | DONGJIN SEMICHEM CO., LTD. (KR) | 2024-07-09 | — | — | US | disclosed |
| CN-108084096-A | 2- phenyl pyrimidine classes compound, preparation method and medical usage | 中国药科大学 | 2018-05-29 | — | — | CN | disclosed |
| US-20170029655-A1 | POLYMERIZABLE COMPOUND, COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY DEVICE, AND ORGANIC EL DEVICE | DIC CORPORATION (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-5728835-A | HYPOTENSIVE AGENTS; ANTIISCHEMIC AGENTS | TOA EIYO, LTD. (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0661266-A1 | Substituted cyclic amine compounds as 5HT2 antagonists | TOA EIYO LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | TP53 4869/4885GAA 374/4885KMT2A 632/4885 |
| US-12030859-B2 | Polymerizable compound, polymerizable composition and optical film | PARG, PUF60, CRY2 | TP53 3231/4885GAA 3401/4885KMT2A 2903/4885 |
| US-20170029655-A1 | POLYMERIZABLE COMPOUND, COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY DEVICE, AND ORGANIC EL DEVICE | OCIAD1, OCIAD2, ELOC | TP53 4534/4885GAA 3310/4885KMT2A 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.